3) Sciffmann R, Ries M: Fabry's disease−an important risk factor for stroke. Lancet 366: 1754-1756, 2005
4) Mehta A, Beck M, Elliott P et al: Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374: 1986-1996, 2009
5) Schiffmann R, Askari H, Timmons M et al: Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18: 1576-1583, 2007